John DE VOS, President at FSSCR, Professor of Medicine at CHU de Montpellier and University of Montpellier, shared a post on X:
“Anti-CD33 CAR-T Cells vs normal hematopoiesis? Protect healthy myeloid cells first: delete CD33 before CAR-T infusion!”
Title: CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
Authors: John F. DiPersio, Guenther Koehne, Nirali N. Shah, Léa Bernard, Hyung C. Suh, Divya Koura, Roni Tamari, Muhammad Umair Mushtaq, Joseph Maakaron, Joseph Rimando, Vanessa E. Kennedy, Sagar S. Patel, Chad Hudson, Michael R. Loken, Christopher A. Slapak, Deborah M. Lloyd, Darren A. Stanizzi, Melissa M. Lee-Sundlov, Sanjana Thosar, Guy Mundelboim, Guangwu Guo, Huanying Gary Ge, Bin E. Li, Juliana Xavier-Ferrucio, Sharon L. Hyzy, Michelle I. Lin, Glen D. Raffel, Brenda W.
Other articles on OncoDaily.